Definitely not! Bet on the validity of the technology (stem cells), Pluristem's production capabilities, and clinical progress.
Too much obsession with management's sins against the poor abused investor. They're doing what they can, and will be much appreciated as soon as we get one approval.
News 
Market Data 
Discover 
